Lynn A Durham Email & Phone Number

Lynn is a biotech entrepreneur and the Founder and CEO of STALICLA (https://stalicla.com/), a clinical-stage biopharmaceutical company advancing precision medicine pipelines for neuropsychiatric and neurological disorders. Driven by a lifelong involvement with the autism community, Lynn has pioneered the creation of the first Neurodevelopmental disorder (NDD) precision medicine platform, initiating a paradigm shift in NDD drug development.Under Lynn's leadership, STALICLA has assembled a team of domain expert drug developers, clinicians, data scientists, and computational biologists to build an advanced clinical-stage precision medicine pipeline, including two phase 2 and one phase 3-ready candidates. Lynn has raised $48M in equity funding and secured large R&D European Grants and a Collaborative Research and Development Agreement with a US NIH agency covering full operational cost of STALICLA's Phase 3 clinical development program (aggregate worth c. $30M).Lynn is an inventor or co-inventor of 11 patent applications, with 8 already granted and has been awarded the Brain Foundation Award for "outstanding leadership towards the advancement of treatments for patients with Neurodevelopmental disorders". As a recognized thought leader in the precision psychiatry space, Lynn is a regular speaker in scientific and industry events and a reviewer for BIOLOGICAL PSYCHIATRY.In addition to the work conducted at STALICLA, Lynn is the Founder of the GATHER Foundation (https://gatherfoundation.ch/network), a Swiss non-profit foundation aiming to promote the establishment of global harmonization standards for the collection of clinical and biological data from patients with Neurodevelopmental disorders. The foundation's objective is to accelerate the transition of the space to the era of precision medicine.

Listed skills include Public Relations, Marketing Communications, Social Media, French, and 30 others.